Portfolio Rapha Capital Management

AsclepiX Therapeutics Raises $5M in New Funding

By Kevin SlawinNovember 15, 2018February 4th, 2021No Comments

AsclepiX Therapeutics
AsclepiX Therapeutics Raises $5M in New Funding
Financing will advance clinical development of the Company’s lead product AXT107
November 15, 2018

Previous PostPoseida Therapeutics: FDA Grants Poseida’s P-BCMA-101 Regenerative Medicine Advanced Therapy (RMAT) Status for Treatment of Multiple Myeloma
Next PostBaltimore-based AsclepiX Therapeutics raises $5M

© 2024 Ponce Therapeutics. Privacy Policy | Terms & Conditions